

# PHARMACOLOGY


Edited by Theoharis C. Theoharides, Ph.D., M.D.











# Pharmacology

Edited by

Theoharis C. Theoharides, Ph.D., M.D.

Associate Professor of Pharmacology and Experimental Therapeutics, Biochemistry, and Psychiatry, and Director of Medical Pharmacology, Tufts University School of Medicine, Boston; Clinical Pharmacologist, Massachusetts Drug Formulary Commission

## Copyright © 1992 by Theoharis C. Theoharides First Edition

All rights reserved. No part of this book may be reproduced in any form or by any electronic or mechanical means, including information storage and retrieval systems, without permission in writing from the publisher, except by a reviewer who may quote brief passages in a review.

Library of Congress Cataloging-in-Publication Data

Pharmacology/ edited by Theoharis C. Theoharides. — 1st ed.

p. cm.

Includes bibliographical references and index.

ISBN 0-316-83935-3: \$29.50

1. Pharmacology. I. Theoharides, Theoharis C.

[DNLM: 1. Drug Therapy—handbooks. 2. Pharmacology—handbooks.

QV 39 P5355]

RM300.P5173 1992

615'.1—dc20

DNLM/DLC

for Library of Congress

91-42155

CIP

Printed in the United States of America MV-NY

# **Pharmacology**

### **Preface**

Pharmacology is the study of the mechanism of action and use of drugs and links biochemistry, morphology, physiology, pathology, and infectious diseases with an understanding of disease at the molecular level. Pharmacology, therefore, bridges the gap between the preclinical and clinical years of medical school, and it is the only discipline among the basic sciences that physicians will actively employ daily throughout their careers. Unfortunately, studying pharmacology in a classroom often seems a dry and overwhelming chore to students who are eager to begin interacting with and treating patients. After 10 years of study and training at Yale University School of Medicine and years of teaching and revising curricula, it became apparent to me that a studentfriendly textbook of pharmacology for medical students on the brink of their first clinical experience should present the essentials of pharmacology as a framework within which a vast amount of clinical information can be organized. Such a book may not appear substantial enough to be useful to a practicing physician, but it should be kept in mind that much of the specific drug information physicians use in the clinical setting is obtained by reading package inserts, the Physicians' Desk Reference, and specialized articles, not by referring back to information they learned from textbooks during their preclinical years. This book is not, therefore, intended for use by physicians as a comprehensive review of pharmacology.

In order to help the student master the essentials of pharmacology, this book differs from other textbooks in the following ways:

- 1. It is designed to be manageable in size.
- 2. All of the tables and figures are original and are classroomtested for effectiveness.
- 3. Learning objectives appear at the beginning of each chapter.
- Chemical structures are included only for purposes of clarification or comparison.

- 5. Figures and tables were conceived to illustrate didactically important principles rather than just to list characteristics of drugs.
- 6. Important principles and terms are emphasized in the text and in tables.
- 7. Summary tables at the end of chapters bring together the mechanism of action, clinical uses, and adverse effects of the drugs discussed in the text.
- 8. Bibliographies are short and are chosen mostly from recent basic or clinical reviews rather than from primary sources.
- 9. National Board type questions are provided to test the most important aspects of the material presented.
- 10. Short explanations of the answers to the National Board type questions are provided.

The presentation of the material makes it easy to absorb and repeatedly emphasizes what is critical for the student to remember. The numerous tables not only organize the material for the student but are excellent review devices.

T. C. T.

## Acknowledgments

I am grateful to the students I have taught at Tufts University School of Medicine, for it was their expressed appreciation that convinced me to undertake this project. I am also very grateful to my family for devotion, patience, support, and understanding during this project.

I am particularly appreciative of the computer work, graphic design, and editing provided by Mr. Jonathan Gorbach (Tufts M'93), without whose help this project might never have been completed.

Many thanks are due to Drs. Bret Taback (Tufts M'91) and Steven Laitan (Tufts M'91) for their notes and editing of this material; to Dr. Spiro Manolidis (Tufts M'88) for his lecture notes; to Mr. Dov Kolker (Tufts M'94) for editing; to Drs. Michael Barza, Edward B. Bromfield, Edward P. Butler, Juan Canoso, Louis Caplan, Modestino Criscitiello, Nathan Estes, Gary Kaplan, Louis Lasagna, Nicolaos Madias, and Richard Norton for their useful comments and corrections; and finally to Dr. Robert Kennison and the administration of Tufts University School of Medicine for their encouragement and support of this project.

Thanks are also due to Sytske Braat, Beth Breslauer, Cyndie Cota, Karen DeLollis, Lisa Moran, Mark Russett, and Linda Tamulaites for their careful and patient typing of the manuscript.

All figures and tables were compiled by the editor and designed by Mr. Jonathan Gorbach.

## **Contributing Authors**

#### Joseph Bertino, M.D.

American Cancer Society Professor of Medicine and Pharmacology, Cornell University Medical College; Co-Chairman, Program of Molecular Pharmacology and Therapeutics, and Attending Physician, Memorial Sloan-Kettering Cancer Center, New York

#### Lazaros Boutis, M.D., D.Sc.

Associate Professor of Medicine and Pharmacology, Aristotelian University School of Medicine; Director, 1st Department of Chemotherapy, Theagenion Cancer Institute, Thessaloniki, Greece

#### Jane F. Desforges, M.D.

Professor of Medicine, Tufts University School of Medicine; Senior Physician and Hematologist, Division of Hematology/Oncology, New England Medical Center, Boston

#### Eric C. Dessain, M.D.

Instructor, Department of Neurology, Harvard Medical School, Boston; Assistant Director, Department of Psychopharmacology, McLean Hospital, Lincoln, Massachusetts

#### Sherwood L. Gorbach, M.D.

Professor of Community Health, Medicine, and Molecular Biology and Microbiology, Tufts University School of Medicine; Attending Physician, New England Medical Center, Boston

#### David J. Greenblatt, M.D.

Professor of Psychiatry, Medicine, and Pharmacology and Experimental Therapeutics, Tufts University School of Medicine; Chief, Division of Clinical Pharmacology, New England Medical Center, Boston

#### Jonathan D. Griswold, M.D., M.S.

Assistant Professor of Anesthesiology, Tufts University School of Medicine; Anesthetist, Department of Anesthesia, New England Medical Center, Boston

#### Gerald T. Keusch, M.D.

Professor of Medicine, Tufts University School of Medicine; Chief, Division of Geographic Medicine/Infectious Diseases, New England Medical Center, Boston

#### Roy L. Kisliuk, Ph.D.

Professor of Biochemistry, and Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston

#### Demetrios G. Lappas, M.D., D.Sc.

Professor of Anesthesiology, Washington University School of Medicine; Director, Section of Cardiothoracic Anesthesia, Barnes Hospital, St. Louis

#### H. Cody Meissner, M.D.

Associate Professor of Pediatrics, Tufts University School of Medicine; Chief, Department of Pediatric Infectious Diseases, New England Medical Center, Boston

#### Kenneth B. Miller, M.D.

Associate Professor of Medicine, Tufts University School of Medicine; Director of Leukemia Service and Bone Marrow Transplantation, Division of Hematology/Oncology, New England Medical Center, Boston

#### Theodore L. Munsat, M.D.

Professor of Neurology, and Pharmacology and Experimental Therapeutics, Tufts University School of Medicine; Director of Neuromuscular Research, New England Medical Center, Boston

#### Clark T. Sawin, M.D.

Professor of Medicine and Physiology, Tufts University School of Medicine; Chief, Endocrine-Diabetes Section, Boston VA Medical Center, Boston

#### Louis Shuster, Ph.D.

Professor of Pharmacology and Experimental Therapeutics, and Director of Graduate Studies, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston

#### John J. Smith, M.D., Ph.D.

Assistant Professor of Medicine, Tufts University School of Medicine; Assistant Director, Cardiac Catheterization Laboratory, New England Medical Center, Boston

#### Egilius L. H. Spierings, M.D., Ph.D.

Lecturer in Neurology, Harvard Medical School; Director, Headache Section, Brigham and Women's Hospital, Boston

#### Theoharis C. Theoharides, Ph.D., M.D.

Associate Professor of Pharmacology and Experimental Therapeutics, Biochemistry, and Psychiatry, and Director of Medical Pharmacology, Tufts University School of Medicine, Boston; Clinical Pharmacologist, Massachusetts Drug Formulary Commission

#### George Triadafilopoulos, M.D., D.Sc.

Assistant Professor of Medicine, University of California, Davis, School of Medicine, Davis; Chief, Gastroenterology Section, Veterans Affairs Medical Center, Martinez, California

#### Anastasios Triantafillou, M.D.

Assistant Professor of Anesthesiology, Washington University School of Medicine; Anesthetist, Department of Anesthesia, Barnes Hospital, St. Louis

#### Marcia Zimmerman, B.A., M.Ed.

Certified Nutritionist, Hayward, California

# **Pharmacology**

此为试读,需要完整PDF请访问: www.ertongbook.com

#### **Notice**

The indications and dosages of all drugs in this book have been recommended in the medical literature and conform to the practices of the general medical community. The medications described do not necessarily have specific approval by the Food and Drug Administration for use in the diseases and dosages for which they are recommended. The package insert for each drug should be consulted for use and dosage as approved by the FDA. Because standards for usage change, it is advisable to keep abreast of revised recommendations, particularly those concerning new drugs.

### **Contents**

Preface

2.

3.

ix Acknowledgments Contributing Authors xiii

1. General Principles and Pharmocokinetics

Theoharis C. Theoharides and Louis Shuster	
Drug Development 2	
Basic Principles 3	
Pharmacodynamics 5	
Pharmacokinetics 12	
David J. Greenblatt	
Metabolism 31	
Roy L. Kisliuk	
Autacoids	49
Theoharis C. Theoharides	
Prostaglandins, Prostacyclin, and Thromboxanes 50	
Leukotrienes 54	
Platelet Activating Factor (PAF) 57	
Kinins and Other Peptides 57	
Renin, Angiotensins, and Atriopeptins 63	
Histamine 65	
Serotonin 73 Immunomodulators 78	
Approaches to Allergy Treatment 82	
Antimionalial Observations	01
Antimicrobial Chemotherapy	91
Sherwood L. Gorbach and Theoharis C. Theoharides	
Concepts of Antibiotic Selection 92	
Cell Wall Active Agents 94	
The Aminoglycosides 110 Quinolones 114	
Quinolones 114 Erythromycin and Clindamycin 116	
Sulfonamides 119	
Roy L. Kisliuk	
Chloramphenicol 122	

1

vi Contents

	The Tetracyclines 124 Nitroimidazoles 128 Antifungal Agents 129 Antimycobacterial Agents 135 Antiviral Agents 141 H. Cody Meissner Antiprotozoal Drugs 148 Gerald T. Keusch Antihelminthic Drugs 161 Gerald T. Keusch
4.	Cancer Chemotherapy 175
	Lazaros Boutis and Theoharis C. Theoharides  General Principles 176  Joseph Bertino  Antineoplastic Agents 180  Alkylating Agents 180  Antimetabolites 197  Intercalators 208  Antimitotics 213  Miscellaneous Antineoplastic Agents 216  Hormones and Their Antagonists 219  Interactions of the Common Antineoplastic Drugs 226  Adoptive Immunotherapy 226
5.	Autonomic Nervous System 239
	Theoharis C. Theoharides and Theodore L. Munsat Sympathetic and Parasympathetic Divisions 240 Synthesis, Secretion, and Metabolism of Neurotransmitters 245 Classification and Action of Neurotransmitter Receptors 255 Acetylcholinesterase Inhibitors 260 Muscarinic Agonists and Antagonists 264 Nicotinic Agonists and Antagonists 266 Agents Affecting Catecholamine Transmission 269 Catecholamine Agonists and Antagonists 273
6.	Central Nervous System 289
	Theoharis C. Theoharides, Eric C. Dessain, and Louis Shuster  Central Neurotransmission and Sites of Drug Action 290  Antipsychotics 293  Agents Used in the Treatment of Parkinsonism 307  Antidepressants 311  Sedatives and Anxiolytic Drugs 323  Anticonvulsants 339

7.	Control of Pain and Inflammation 363  Theoharis C. Theoharides and Egilius L. H. Spierings  The Nature of Pain 364  Anti-Inflammatory and Non-Narcotic Analgesics 368  Anti-Arthritic Agents 381  Other Anti-Inflammatory Agents 383  Narcotic Analgesics 391  Narcotic Addiction 404  Cancer and Other Chronic Pain Control 405  Antimigraine Agents 408
8.	Anesthetics 421  Demetrios G. Lappas, Anastasios Triantafillou, Jonathan D. Griswold, and Theoharis C. Theoharides  Overview 422  Inhalation Anesthetics 425  Common Characteristics of Inhalation Anesthetics 430  Specific Inhalation Anesthetic Agents 436  Intravenous Anesthetics 440  Local Anesthetics 452
9.	Cardiovascular Agents Theoharis C. Theoharides and John J. Smith Hemostasis 466 Control of Lipid Disorders 476 Drugs that Affect Blood Flow and Hemopoiesis 482 Jane F. Desforges and Kenneth B. Miller Digitalis Glycosides 486 Antianginal Agents 489 Antiarrhythmic Agents 495 Antihypertensives 505 Congestive Heart Failure and Pulmonary Edema 526
10.	Hormones and Agents Affecting Endocrine and Metabolic Function Theoharis C. Theoharides and Clark T. Sawin Adrenal Corticosteroids 538 Sex Hormones and Their Analogues 547 Thyroid Hormones and Inhibitors of Their Synthesis Agents Affecting Calcium and Bone 555 Agents Affecting Glucose Metabolism 560
11.	Agents for the Treatment of Digestive and Liver Diseases 569

George Triadafilopoulos and Theoharis C. Theoharides

Agents for Gastroesophageal Reflux and Peptic Ulcer

Disease

570

viii Contents

Agents for the Treatment of Inflammatory Bowel Disease Agents for the Treatment of Diarrheal and Motility	575
Disorders 578	
Agents for the Treatment of Liver Disease 587	
Agents for the Treatment of Pancreatic Disease 589	
Appendix A. Nutrition and Pharmacology  Marcia Zimmerman	593
<b>Appendix B. Toxicology</b> Theoharis C. Theoharides	601
Appendix C. Drug Interactions Theoharis C. Theoharides	609
Abbreviations 615	
Index 623	

# General Principles and Pharmacokinetics

Theoharis C. Theoharides Louis Shuster

#### **Objectives**

You should understand the following terms and topics:

#### Terms

Absorption

Agonist, antagonist

Antagonism

Area under the curve (AUC)

Bioavailability Bolus injection

Clearance

Competitive versus

noncompetitive antagonists

Distribution

Enzyme induction

Excretion

First-pass effect

Half-life

Hepatic blood flow-limited

elimination

Microsomal mixed-function oxidase

system

Minimum therapeutic concentration

Partial agonist, antagonist

Peak and trough concentrations

Pharmacodynamics

Pharmacokinetics
Phase I and phase II

biotransformation

 $pK_a$ 

Plateau, ceiling

Receptor

Slow acetylator

Steady-state concentration

Synergism

Termination of action

Therapeutic index Weak acid, weak base

Zero-order, first-order

elimination

#### Topics .

The relationship between physiochemical properties and drug distribution

The concept of volume of distribution

The time required to obtain steady state or drug elimination

The relationship between half-life and elimination rate constant

The units defining important terms

The differences between drug potency, affinity, and efficacy

The definition of therapeutic index as LD<sub>50</sub> over ED<sub>50</sub>

How to calculate plasma concentrations and half-life from a curve showing attainment of steady state or drug elimination

Principal sites of metabolism and different types of biotransformation reactions

Metabolism, p. 31, was written by Roy L. Kisliuk. Pharmacokinetics, p. 12, was written by David J. Greenblatt.